The Pricing and Reimbursement Environment for Metabolic Disease Therapies


March 1, 2011
SKU: DECR6187719
License type:
Table of Contents Related Reports
Introduction:

Metabolic disorders are among the most common serious diseases in the world, and their prevalence is increasing rapidly in many countries. Governments and other healthcare sponsors have made the prevention and treatment of metabolic disorders a priority and generally offer generous coverage of drugs for these diseases. Spending in this therapeutic area is growing rapidly, prompting payers to review their cost-containment strategies. Drug manufacturers need to be aware of the barriers to access they will face in marketing metabolic disease therapies in major pharmaceutical markets.

Questions Answered in This Report:
  • The United States has the highest overall prescription drug prices of any of the major pharmaceutical markets. How do the prices of metabolic disease therapies in Europe and Japan compare with U.S. prices? Which metabolic disease therapies have the highest international prices?
  • In the United States, the majority of commercial health plans assign most metabolic disease therapies to tiers 2 or 3 of their formularies. Which leading drugs have the most and least favorable placement? How do Medicare plans compare with commercial plans in their positioning of metabolic disease therapies? Which coverage restrictions are most commonly applied to metabolic drugs?
  • A recent Decision Resources survey of 50 endocrinologists and 50 primary care physicians in the United States found widespread concern about barriers to access to metabolic disease therapies. To what extent do out-of-pocket costs restrict patients' access to, and compliance with, metabolic disease therapies? What impact do coverage restrictions have on access to medications? What changes in cost containment are likely in the next five years?
  • The French healthcare system reimburses a substantial proportion of the cost of metabolic drugs. What is the standard reimbursement rate for drugs in this therapeutic area? For which metabolic disorders can patients qualify for exemption from out-of-pocket costs for medications?
  • German physicians tend to rely very heavily on generics for the treatment of some of the most common metabolic disorders. What national targets have been set for the prescribing of generic antidiabetics, statins, and bisphosphonates? What pressures are exerted on German physicians to prescribe economically?
  • The Italian healthcare system covers the full cost of most metabolic disease therapies but imposes strict controls on the prescription of many of these drugs. Which drugs are included in the Register of Antidiabetic Drugs Subject to Monitoring? How has the Agenzia Italiana del Farmaco (AIFA; Italian Medicines Agency) used restrictive notes to control the use of treatments for dyslipidemia, osteoporosis, and gout?
  • The influence of the National Institute for Health and Clinical Excellence (NICE) on the healthcare system in England, Wales, and Northern Ireland can scarcely be overstated. What guidance has NICE issued on the management of metabolic disorders? What other methods has the U.K. government used to control spending on metabolic disease therapies?
Scope:

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Indication focus: Diabetes, dyslipidemia, osteoporosis, gout.

Primary research: Survey of 50 endocrinologists and 50 primary care physicians in the United States.

Pricing data: Prices of 20 best-selling metabolic drugs in seven major markets.

Reimbursement: Detailed Fingertip Formulary data on the formulary status and coverage restrictions of 30 drugs in commercial and Medicare plans in the United States; reimbursement policies in France, Germany, Italy, Spain, the United Kingdom, and Japan.

General market access environment: Concise overviews of health insurance coverage, pharmaceutical reimbursement, and cost-containment trends that impact the market for metabolic disease in each country under review.

Please note, the PDF e-mail from publisher version of this report is for a global site license.


Additional Information

Mentioned in this report:

Companies:
  • Abiogen
  • Amylin
  • Astellas
  • AstraZeneca
  • Bayer
  • Biovail
  • Bouchari Recordati
  • Bristol
  • Myers Squibb
  • Daiichi Sankyo
  • Dainippon Sumitomo
  • DepoMed
  • Eisai
  • Eli Lilly
  • Fournier Pharma
  • GlaxoSmithKline
  • Ipsen
  • Kaken Seiyaku
  • Kissei
  • Kowa
  • Menarini
  • Merck & Co.
  • Mochida
  • Molteni Farmaceutici
  • Novartis
  • Novo Nordisk
  • NPS
  • Nycomed
  • Ono
  • Pfizer
  • Prometheus Laboratories
  • Roche
  • Sanofi
  • Aventis
  • Sanwa Kagaku
  • Servier
  • Seven Seas
  • Shionogi
  • Solvay
  • Solvay
  • SPA
  • Takeda
  • Temmler
  • Tori Yakuhin
  • UCB
  • Uri Pharma
  • Warner
  • Chilcott
  • Watson
Drugs:
  • Acarbose
  • Alendronate
  • Allopurinol
  • Amfepramone
  • Atorvastatin
  • Atorvastatin/amlodipine
  • Benzbromarone
  • Bezafibrate
  • Calcitonin (intranasal)
  • Cholestyramine
  • Colchicine
  • Colesevelam
  • Conjugated estrogen/MPA
  • Estradiol
  • Etidronate
  • Exenatide
  • Ezetimibe
  • Ezetimibe/simvastatin
  • Febuxostat
  • Fenofibrate
  • Fenofibric acid
  • Fluvastatin
  • Gemfibrozil
  • Gliclazide
  • Glimepiride
  • Glipizide
  • Glyburide/glibenclamide
  • Ibandronate
  • Insulin aspart
  • Insulin detemir
  • Insulin glargine
  • Insulin glulisine
  • Insulin lispro
  • Insulin, neutral protamine Hagedorn
  • Insulins, regular human
  • Ipriflavone
  • Liraglutide
  • Lovastatin
  • Mazindol
  • Menatetrenone
  • Metformin
  • Metformin/glipizide
  • Metformin/glyburide
  • Miglitol
  • Minodronate
  • Mitiglinide
  • Nateglinide
  • Niacin (extended release)
  • Niacin/laropiprant (extended release)
  • Niacin/lovastatin (extended release)
  • Niacin/simvastatin (extended release)
  • Omega
  • 3 acid ethyl esters
  • Orlistat
  • Phentermine
  • Pioglitazone
  • Pioglitazone/glimepiride
  • Pioglitazone/metformin
  • Pioglitazone/metformin (extended release)
  • Pitavastatin
  • Pramlintide
  • Pravastatin
  • Probenecid
  • Raloxifene
  • Repaglinide
  • Risedronate
  • Rosiglitazone
  • Rosiglitazone/glimepiride
  • Rosiglitazone/metformin
  • Rosuvastatin
  • Saxagliptin
  • Sibutramine
  • Simvastatin
  • Sitagliptin
  • Sitagliptin/metformin
  • Strontium ranelate
  • Teriparatide
  • Tibolone
  • Vildagliptin
  • Vildagliptin/metformin
  • Voglibose
  • Zoledronate

More Endocrinology/Metabolics reports by Decision Resources

Controversies in Diagnosing Metabolic Diseases: Can Biomarkers and Diagnostic Tools Resolve Them? by Decision Resources
A vast majority of surveyed physicians point to the need for biomarker-based testing for metabolic diseases, but controversies about how these diseases are diagnosed, managed, ...
Special Report: Dealmaking and Industry Outlook in Niche Metabolic Diseases by Decision Resources
Introduction: Pharmaceutical companies should take a keener interest in developing therapies for niche metabolic diseases. Biologics will enjoy 12 years of marketing exclusivity under the ...
ORPHAN DISEASE SERIES - Cystic Fibrosis: Will New Agents Emerge as First-Line Therapies? by Decision Resources
The cystic fibrosis (CF) market is poised for significant change. The next generation of CF treatments all target the central mechanism responsible for organ damage ...
See all reports like this >>

 
Research assistance
We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 
Related Markets
 
 

Share this report


Other tasks

 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!